REGN - Regeneron Pharmaceuticals misses top-line and bottom-line estimates; updates FY24 outlook May, 02 2024 06:32 AM Regeneron Pharmaceuticals Inc. 2024-05-02 06:32:10 ET More on Regeneron Pharmaceuticals Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate Regeneron, Mammoth in pact to develop CRISPR-based gene editing therapies For further details see: Regeneron Pharmaceuticals misses top-line and bottom-line estimates; updates FY24 outlook